MedTrace Logo

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

NCT01502527 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-03-20

No results posted yet for this study

Summary

Based on previous data published on the SERM properties of Femarelle, the investigators hypothesized that Femarelle could be a potential treatment for Vulvo-vaginal atrophy(VVA) symptoms. The current study was a pilot study to examine the effect of Femarelle® on VVA symptoms in symptomatic post-menopausal women.

Conditions

  • Vulvo Vaginal Atrophy

Interventions

DIETARY_SUPPLEMENT

Femarelle

Twice daily oral treatment with Femarelle

Sponsors & Collaborators

  • Se-cure Pharmaceuticals Ltd.

    collaborator INDUSTRY

  • Dr. Lila Nachtigall Rapid Medical Research, New York

    lead OTHER

Principal Investigators

  • Lila Nachtigall, MD · Rapid Medical Research of New York

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01502527 on ClinicalTrials.gov